Poliumoside |
Catalog No.GN10320
One-Click Copy Product Info
|
Poliumoside is a caffeoylated phenylpropanoid glycoside.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 94079-81-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Poliumoside is a caffeoylated phenylpropanoid glycoside [1]. Poliumoside inhibits the formation of advanced glycation end products (AGEs, IC₅₀ = 19.69μM) and rat lens aldose reductase (RLAR, IC₅₀ = 8.47μM) [2]. Poliumoside has antioxidant and cell aggregation inhibitory effects [3-4].
In bone mesenchymal stem cells, Poliumoside (75μM, 150μM, 225μM, 300μM, 375μM; 24h) inhibits HGHF-induced BMSC ferroptosis [5]. In A549 cells, Poliumoside (10μM, 20μM, 40μM; 24h) alleviates TNF-α-induced cell damage by simultaneously regulating the NF-κB pathway and the Nrf2 pathway [6].
In Transient middle cerebral artery occlusion mouse model, Poliumoside (5mg/kg, 10mg/kg, 15mg/kg; ip; 3d) improves neurological function and reduces infarct volume after stroke [7]. In the cognitive dysfunction rat model, Poliumoside (5mg/kg, 10mg/kg; ip; 21d) treatment improved cognitive capacity in rats in morris water maze and recognition tests [8].
References:
[1]. He ZD, Lau KM, Xu HX, et al. Antioxidant activity of phenylethanoid glycosides from Brandisia hancei. Journal of ethnopharmacology. 2000 Aug 1; 71(3): 483-486.
[2]. Yu SY, Lee IS, Jung SH, et al. Caffeoylated phenylpropanoid glycosides from Brandisia hancei inhibit advanced glycation end product formation and aldose reductase in vitro and vessel dilation in larval zebrafish in vivo. Planta medica. 2013 Dec; 79(18): 1705-1709.
[3]. De Marino S, Festa C, Zollo F, et al. Antioxidant activity of phenolic and phenylethanoid glycosides from Teucrium polium L. Food Chemistry. 2012 Jul 1;133(1): 21-28.
[4]. Tatli II, Takamatsu S, Khan I, et al. Screening for free radical scavenging and cell aggregation inhibitory activities by secondary metabolites from Turkish Verbascum species [J]. Zeitschrift für Naturforschung C. 2007 Oct 1; 62(9-10): 673-678.
[5]. Xu CY, Xu C, Xu YN, et al. Poliumoside protects against type 2 diabetes-related osteoporosis by suppressing ferroptosis via activation of the Nrf2/GPX4 pathway. Phytomedicine. 2024 Mar 1; 125: 155342.
[6]. Zheng JN, Zhuo JY, Nie J, et al. Phenylethanoid glycosides from Callicarpa kwangtungensis Chun attenuate TNF-α-induced cell damage by inhibiting NF-κB pathway and enhancing Nrf2 pathway in A549 cells. Frontiers in pharmacology. 2021 Jul 7; 12: 693983.
[7]. Gao Y, Wang J, Zhang C, et al. Poliumoside alleviates microglia-mediated inflammation and blood-brain barrier disruption via modulating the polarization of microglia after ischemic stroke in mice. Phytomedicine. 2025 May 23: 156881.
[8]. Zuo Y, Chen B, Li X, et al. Poliumoside inhibits apoptosis, oxidative stress and neuro-inflammation to prevent intracerebroventricular Streptozotocin-induced cognitive dysfunction in Sprague-Dawley Rats: in in-vivo, in-vitro and in-silico study. Folia Morphologica. 2024 Oct 23.
| Cell experiment [1]: | |
Cell lines | Bone mesenchymal stem cells (BMSCs) |
Preparation Method | After BMSCs were treated with different Poliumoside concentrations for 24h, the existing culture medium was replaced with culture medium containing 10% CCK-8 reagent to form the surgical solution. Thereafter, the cells were incubated at a constant temperature of 37°C for 2h. |
Reaction Conditions | 75μM, 150μM, 225μM, 300μM, 375μM; 24h |
Applications | Poliumoside inhibits HGHF-induced BMSC ferroptosis. |
| Animal experiment [2]: | |
Animal models | Transient middle cerebral artery occlusion (tMCAO) mouse model |
Preparation Method | After tMCAO, Pol was injected intraperitoneally into mice and EDB was injected via the tail vein until the time of sacrifice. A total of 190 C57BL/6 mice were utilized in this study. In the initial experiment, mice were randomly divided into five groups: (1) tMCAO group (received an equal volume of 0.9% saline), (2) Poliumoside-L low-dose group (5mg/kg/day), (3) Poliumoside-M middle-dose group (10mg/kg/day), (4) Poliumoside-H high-dose group (15mg/kg/day) and (5) positive control group (EDB 1.5mg/kg) |
Dosage form | 5mg/kg, 10mg/kg, 15mg/kg; ip; 3d |
Applications | Poliumoside improves neurological function and reduces infarct volume after stroke. |
References: | |
| Cas No. | 94079-81-9 | SDF | |
| Chemical Name | [6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-2-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | ||
| Canonical SMILES | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OCCC3=CC(=C(C=C3)O)O)O)OC4C(C(C(C(O4)C)O)O)O)OC(=O)C=CC5=CC(=C(C=C5)O)O)O)O)O | ||
| Formula | C35H46O19 | M.Wt | 770.73 |
| Solubility | ≥ 38.55mg/mL in EtOH | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2975 mL | 6.4874 mL | 12.9747 mL |
| 5 mM | 259.5 μL | 1.2975 mL | 2.5949 mL |
| 10 mM | 129.7 μL | 648.7 μL | 1.2975 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)